<DOC>
	<DOCNO>NCT00001989</DOCNO>
	<brief_summary>This study involve GLQ223 administration patient previously expose , receive least 9 month zidovudine therapy . Efficacy evaluation include survival , opportunistic infection , T4 cell count , assessment viral load .</brief_summary>
	<brief_title>A Randomized Phase II Efficacy , Activity Safety Study GLQ223 Alone Combination With Zidovudine Symptomatic HIV-Infected Patients Without Prior Treatment With GLQ223 Trichosanthin</brief_title>
	<detailed_description>The study involve randomization patient 200-500 T4 cell AIDS ARC one three treatment arm : zidovudine alone , GLQ223 alone , GLQ223 plus zidovudine . Patients randomize receive GLQ223 receive infusion every three week 45 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Trichosanthin</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Aerosolized pentamidine , trimethoprim/sulfamethoxazole , dapsone PCP prophylaxis . Chronic suppressive therapy follow infection : Toxoplasmosis ( pyrimethamine , sulfadiazine , clindamycin ) . Cryptococcosis ( fluconazole ) . Candidiasis ( ketoconazole ) . Herpes simplex virus ( acyclovir ) . Mycobacterium avium ( isoniazid , clofazimine , amikacin , rifampin , rifabutin , ethambutol , drug write permission sponsor ) . Required : Patients whose CD4+ count fall 200 two consecutive measurement must receive prophylaxis PCP clinically indicate condition . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : An active AIDSdefining opportunistic infection . Evidence AIDS dementia complex active neurologic disease , include progressive multifocal leukoencephalopathy ( PML ) , poorly control seizure disorder active CNS infection . Any condition Investigator 's opinion sufficient prevent adequate compliance study . Concurrent Medication : Excluded : Therapeutic agent specific HIV disease receive FDA approval . Biologic response modifier , include interferon , interleukin2 ( IL2 ) , leukocyte stimulating hormone ( GMCSF , GCSF ) . Patients follow exclude : An active AIDSdefining opportunistic infection . Evidence AIDS dementia complex active neurologic disease , include progressive multifocal leukoencephalopathy ( PML ) , poorly control seizure disorder active CNS infection . Participation clinical study , include investigational therapy HIV infection . Any condition Investigator 's opinion sufficient prevent adequate compliance study . History prior use GLQ223 trichosanthin presence antiGLQ223 serum IgG antibody measure Western blot . Inability provide write informed consent . Prior Medication : Excluded : History prior use GLQ223 trichosanthin presence antiGLQ serum IgG antibody measure Western blot . Excluded within 30 day prior enrollment : Use unapproved therapeutic agent specific HIV disease , include ddC . Use biologic response modifier , include interferon , interleukin2 , leukocyte stimulating hormone ( GMCSF , GCSF ) . Patients follow : HIV positive ELISA confirmation Western blot . Symptomatic AIDSRelated Complex AIDS CDC classification . History zidovudine therapy dose equal 300 mg daily least 9 consecutive month immediately prior entry study . CD4 count equal 200 equal less 500 ( mean 2 reading one week apart ) . Ability give inform consent . Required : Zidovudine therapy dose equal 300 mg daily least 9 month immediately prior entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 1992</verification_date>
	<keyword>Trichosanthin</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Zidovudine</keyword>
</DOC>